XML 46 R34.htm IDEA: XBRL DOCUMENT v3.25.2
REVENUES - Summary of Total Revenues (Details) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Disaggregation of Revenue [Line Items]        
Total revenues $ 7,082 $ 6,954 $ 13,749 $ 13,640
U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 5,051 4,941 9,719 9,574
Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 1,189 1,133 2,273 2,292
Rest of World        
Disaggregation of Revenue [Line Items]        
Total revenues 842 879 1,757 1,774
Total product sales        
Disaggregation of Revenue [Line Items]        
Total revenues 7,054 6,912 13,668 13,559
Total product sales | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 5,038 4,916 9,669 9,525
Total product sales | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 1,178 1,118 2,251 2,262
Total product sales | Rest of World        
Disaggregation of Revenue [Line Items]        
Total revenues 838 878 1,747 1,772
Total HIV        
Disaggregation of Revenue [Line Items]        
Total revenues 5,088 4,745 9,675 9,088
Total HIV | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 4,096 3,821 7,760 7,226
Total HIV | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 624 571 1,177 1,167
Total HIV | Rest of World        
Disaggregation of Revenue [Line Items]        
Total revenues 368 353 738 695
Biktarvy        
Disaggregation of Revenue [Line Items]        
Total revenues 3,530 3,232 6,679 6,177
Biktarvy | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 2,799 2,585 5,272 4,900
Biktarvy | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 429 370 804 735
Biktarvy | Rest of World        
Disaggregation of Revenue [Line Items]        
Total revenues 302 277 603 542
Descovy        
Disaggregation of Revenue [Line Items]        
Total revenues 653 485 1,239 911
Descovy | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 601 434 1,139 805
Descovy | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 24 25 45 51
Descovy | Rest of World        
Disaggregation of Revenue [Line Items]        
Total revenues 28 26 55 55
Genvoya        
Disaggregation of Revenue [Line Items]        
Total revenues 377 440 741 843
Genvoya | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 322 372 627 704
Genvoya | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 40 45 79 95
Genvoya | Rest of World        
Disaggregation of Revenue [Line Items]        
Total revenues 16 23 35 44
Odefsey        
Disaggregation of Revenue [Line Items]        
Total revenues 298 315 579 626
Odefsey | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 221 233 436 457
Odefsey | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 66 72 123 148
Odefsey | Rest of World        
Disaggregation of Revenue [Line Items]        
Total revenues 11 10 20 21
Symtuza - Revenue share        
Disaggregation of Revenue [Line Items]        
Total revenues 124 168 238 309
Symtuza - Revenue share | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 88 131 170 236
Symtuza - Revenue share | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 33 34 62 67
Symtuza - Revenue share | Rest of World        
Disaggregation of Revenue [Line Items]        
Total revenues 3 3 6 6
Other HIV        
Disaggregation of Revenue [Line Items]        
Total revenues 107 105 198 222
Other HIV | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 65 65 115 125
Other HIV | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 33 25 63 70
Other HIV | Rest of World        
Disaggregation of Revenue [Line Items]        
Total revenues 9 15 19 27
Total Liver Disease        
Disaggregation of Revenue [Line Items]        
Total revenues 795 832 1,553 1,569
Total Liver Disease | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 413 431 748 816
Total Liver Disease | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 170 142 338 279
Total Liver Disease | Rest of World        
Disaggregation of Revenue [Line Items]        
Total revenues 211 259 467 474
Sofosbuvir/Velpatasvir        
Disaggregation of Revenue [Line Items]        
Total revenues 342 476 687 881
Sofosbuvir/Velpatasvir | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 184 267 351 515
Sofosbuvir/Velpatasvir | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 81 84 161 163
Sofosbuvir/Velpatasvir | Rest of World        
Disaggregation of Revenue [Line Items]        
Total revenues 76 126 175 203
Vemlidy        
Disaggregation of Revenue [Line Items]        
Total revenues 252 243 504 467
Vemlidy | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 122 117 222 212
Vemlidy | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 13 11 24 22
Vemlidy | Rest of World        
Disaggregation of Revenue [Line Items]        
Total revenues 117 115 257 233
Other Liver Disease        
Disaggregation of Revenue [Line Items]        
Total revenues 201 113 362 221
Other Liver Disease | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 106 47 175 89
Other Liver Disease | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 76 47 152 94
Other Liver Disease | Rest of World        
Disaggregation of Revenue [Line Items]        
Total revenues 19 19 35 38
Veklury        
Disaggregation of Revenue [Line Items]        
Total revenues 121 214 423 769
Veklury | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 51 76 250 391
Veklury | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 19 53 41 123
Veklury | Rest of World        
Disaggregation of Revenue [Line Items]        
Total revenues 50 85 132 255
Total Oncology        
Disaggregation of Revenue [Line Items]        
Total revenues 849 841 1,606 1,629
Total Oncology | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 427 474 808 904
Total Oncology | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 291 275 547 537
Total Oncology | Rest of World        
Disaggregation of Revenue [Line Items]        
Total revenues 131 92 252 188
Total Cell Therapy        
Disaggregation of Revenue [Line Items]        
Total revenues 485 521 949 1,001
Total Cell Therapy | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 203 250 403 475
Total Cell Therapy | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 196 206 376 400
Total Cell Therapy | Rest of World        
Disaggregation of Revenue [Line Items]        
Total revenues 86 66 171 126
Tecartus        
Disaggregation of Revenue [Line Items]        
Total revenues 92 107 171 207
Tecartus | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 41 63 82 118
Tecartus | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 41 37 72 73
Tecartus | Rest of World        
Disaggregation of Revenue [Line Items]        
Total revenues 9 7 17 16
Yescarta        
Disaggregation of Revenue [Line Items]        
Total revenues 393 414 779 794
Yescarta | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 162 186 321 357
Yescarta | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 154 169 304 327
Yescarta | Rest of World        
Disaggregation of Revenue [Line Items]        
Total revenues 77 58 154 110
Trodelvy        
Disaggregation of Revenue [Line Items]        
Total revenues 364 320 657 628
Trodelvy | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 224 224 405 429
Trodelvy | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 96 69 171 137
Trodelvy | Rest of World        
Disaggregation of Revenue [Line Items]        
Total revenues 44 26 81 62
Total Other        
Disaggregation of Revenue [Line Items]        
Total revenues 202 280 410 504
Total Other | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 52 115 104 188
Total Other | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 73 77 149 156
Total Other | Rest of World        
Disaggregation of Revenue [Line Items]        
Total revenues 77 88 158 160
AmBisome        
Disaggregation of Revenue [Line Items]        
Total revenues 129 151 268 294
AmBisome | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 7 17 13 31
AmBisome | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 65 69 132 139
AmBisome | Rest of World        
Disaggregation of Revenue [Line Items]        
Total revenues 56 65 123 124
Other        
Disaggregation of Revenue [Line Items]        
Total revenues 73 130 143 209
Other | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 44 98 91 156
Other | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 8 8 16 18
Other | Rest of World        
Disaggregation of Revenue [Line Items]        
Total revenues 21 24 35 36
Royalty, contract and other revenues        
Disaggregation of Revenue [Line Items]        
Total revenues 27 41 81 81
Royalty, contract and other revenues | U.S.        
Disaggregation of Revenue [Line Items]        
Total revenues 13 25 49 49
Royalty, contract and other revenues | Europe        
Disaggregation of Revenue [Line Items]        
Total revenues 10 15 21 30
Royalty, contract and other revenues | Rest of World        
Disaggregation of Revenue [Line Items]        
Total revenues $ 4 $ 1 $ 10 $ 2